生物制剂依从性对类风湿关节炎治疗达标的影响(5)
[15]Strand V，GreenbergJD，Griffith J，Ban Y，Saunders KC，GargV，Li G，Ganguli A.Impact of treatment with biologic agentson the use of mechanical devices among rheumatoid arthritispatients in a large US patient registry.Arthritis Care Res(Hob-oken)，2016，68(7)：914-921.
[16]Bluett J，Morgan C，Thurston L，Plant D，Hyrich KL，Morgan AW，Wilson AG，Isaacs JD，Cordingley L，BartonA：BRAGGSS.Impact of inadequate adherence on response tosubcutaneously administered anti-tumour necrosis factor drugs：results from the Biologics in Rheumatoid Arthritis Genetics andGenomics Study Syndicate cohort.Rheumatology(Oxford)，2015，54(3)：494-499.
, 百拇医药
[17]Ghiti Moghadam M，Vonkeman HE，Ten Klooster PM，TekstraJ，van Schaardenburg D，Starmans-Kool M，Brouwer E，BosR，Lems WF，Colin EM，Allaart CF，Meek IL，Landewe R，Bernelot Moens HJ，van Riel PL，van de Laar MA，JansenTL：Dutch National POET Collaboration.Stopping tumor necrosisfactor inhibitor treatment in patients with established rheumatoidarthritis in remission or with stable low disease activity：a pragmaticmulticenter，open-label randomized controlled trial.Arthritis Rhe-umatol，2016，68(8)：1810-1817.
, 百拇医药
[18]Campbell NKJ，Saadeldin K，De Vera MA.The duality ofeconomic issues with medication non-adherence in patients withinflammatory arthritis.Curr Rheumatol Rep，2017，19(10)：66.
[19]Lathia U，Ewara EM，Nantel F.Impact of adherence tobiological agents on health care resource utilization for patientsover the age of 65 years with rheumatoid arthritis.Patient PreferAdherence，2017，11：1133-1142.
[20]Favalli EG，Sinigaglia L，Becciolini A，Grosso V，Gorla R，Bazzani C，Atzeni F，Sarzi Puttini PC，Fusaro E，PelleritoR，Caporali R.Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to othersubcutaneous tumor necrosis factor inhibitors：real-life data fromthe LORHEN registry.Int J Rheum Dis，2018，21(2)：422-430.
, 百拇医药
[21]Ebina K，Hashimoto M，Yamamoto W，Ohnishi A，Kabata D，Hirano T，Hara R，Katayama M，Yoshida S，Nagai K，SonY，Amuro H，Akashi K，Fujimura T，Hirao M，Yamamoto K，Shintani A，Kumanogoh A，Yoshikawa H.Drug retention anddiscontinuation reasons between seven biologics in patients withrheumatoid arthritis-The ANSWER cohort study.PLoS One，2018，13(3)：c0194130.
[22]Calvo-Alen J，Monteagudo I，Salvador G，Vazquez-RodriguezTR，Tovar-Beltran JV，Vela P，Maceiras F，Bustabad S，Roman-Ivorra JA，Diaz-Miguel C，Rosas J，Raya E，CarmonaL，Cea-Calvo L，Arteaga MJ，Fernandez S，Marras C.Non-adherence to subcutaneous biological medication in patients withrheumatoid arthritis：a multicentre，non-interve-ntional study.Clin Exp Rheumatol，2017，35(3)：423-430., 百拇医药(陈乐锋 马剑达 李谦华 戴冽)
[16]Bluett J，Morgan C，Thurston L，Plant D，Hyrich KL，Morgan AW，Wilson AG，Isaacs JD，Cordingley L，BartonA：BRAGGSS.Impact of inadequate adherence on response tosubcutaneously administered anti-tumour necrosis factor drugs：results from the Biologics in Rheumatoid Arthritis Genetics andGenomics Study Syndicate cohort.Rheumatology(Oxford)，2015，54(3)：494-499.
, 百拇医药
[17]Ghiti Moghadam M，Vonkeman HE，Ten Klooster PM，TekstraJ，van Schaardenburg D，Starmans-Kool M，Brouwer E，BosR，Lems WF，Colin EM，Allaart CF，Meek IL，Landewe R，Bernelot Moens HJ，van Riel PL，van de Laar MA，JansenTL：Dutch National POET Collaboration.Stopping tumor necrosisfactor inhibitor treatment in patients with established rheumatoidarthritis in remission or with stable low disease activity：a pragmaticmulticenter，open-label randomized controlled trial.Arthritis Rhe-umatol，2016，68(8)：1810-1817.
, 百拇医药
[18]Campbell NKJ，Saadeldin K，De Vera MA.The duality ofeconomic issues with medication non-adherence in patients withinflammatory arthritis.Curr Rheumatol Rep，2017，19(10)：66.
[19]Lathia U，Ewara EM，Nantel F.Impact of adherence tobiological agents on health care resource utilization for patientsover the age of 65 years with rheumatoid arthritis.Patient PreferAdherence，2017，11：1133-1142.
[20]Favalli EG，Sinigaglia L，Becciolini A，Grosso V，Gorla R，Bazzani C，Atzeni F，Sarzi Puttini PC，Fusaro E，PelleritoR，Caporali R.Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to othersubcutaneous tumor necrosis factor inhibitors：real-life data fromthe LORHEN registry.Int J Rheum Dis，2018，21(2)：422-430.
, 百拇医药
[21]Ebina K，Hashimoto M，Yamamoto W，Ohnishi A，Kabata D，Hirano T，Hara R，Katayama M，Yoshida S，Nagai K，SonY，Amuro H，Akashi K，Fujimura T，Hirao M，Yamamoto K，Shintani A，Kumanogoh A，Yoshikawa H.Drug retention anddiscontinuation reasons between seven biologics in patients withrheumatoid arthritis-The ANSWER cohort study.PLoS One，2018，13(3)：c0194130.
[22]Calvo-Alen J，Monteagudo I，Salvador G，Vazquez-RodriguezTR，Tovar-Beltran JV，Vela P，Maceiras F，Bustabad S，Roman-Ivorra JA，Diaz-Miguel C，Rosas J，Raya E，CarmonaL，Cea-Calvo L，Arteaga MJ，Fernandez S，Marras C.Non-adherence to subcutaneous biological medication in patients withrheumatoid arthritis：a multicentre，non-interve-ntional study.Clin Exp Rheumatol，2017，35(3)：423-430., 百拇医药(陈乐锋 马剑达 李谦华 戴冽)